Search Results - "Mansutti, M"

What to do in an oncology department to face the new COVID-19 era challenges? by Garattini, S. K., Bin, A., Donato, R., Mansutti, M., Rizzato, S., Troiero, G., Candoni, A., Fanin, R., Fasola, G.

“…Italy was the first European country to be hit by COVID-19 pandemic. As a consequence, Italian oncologists had to guarantee essential treatments although…”
Get full text

A risk score integrating lymphocytes ratios (LRs) and lactate dehydrogenase (LDH) levels to predict prognosis in metastatic breast cancer (MBC) patients by Pelizzari, G., Gerratana, L., Basile, D., Zago, S., Vitale, M.G., Bartoletti, M., Lisanti, C., Fanotto, V., Corvaja, C., Bortot, L., Liguori, A., Cinausero, M., Russo, S., Andreetta, C., Bonotto, M., Mansutti, M., Minisini, A.M., Curcio, F., Fasola, G., Puglisi, F.

Get full text

Unplanned presentations of cancer outpatients: a retrospective cohort study by Aprile, G., Pisa, F. E., Follador, A., Foltran, L., De Pauli, F., Mazzer, M., Lutrino, S., Sacco, C. S., Mansutti, M., Fasola, G.

“…Purpose As a result of the growing cancer incidence and the increasing trend towards chemotherapy treatment, a higher number of cancer outpatients ask for…”
Get full text

Small luminal-like breast cancer: determinants of adjuvant chemotherapy use by Bettini, A, Gerratana, L, Pelizzari, G, Bonotto, M, Basile, D, Vitale, M G, Bozza, C, Bartoletti, M, Fanotto, V, Lisanti, C, Cinausero, M, Mansutti, M, Minisini, A M, Fasola, G, Puglisi, F

Get full text

Neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios in breast cancer by Gerratana, L, Zago, S, Basile, D, Vitale, M G, Pelizzari, G, Bonotto, M, Bozza, C, Bartoletti, M, Fanotto, V, Lisanti, C, Cinausero, M, Barban, S, Lera, M, Venuti, I, Mansutti, M, Minisini, A M, Fasola, G, Curcio, F, Puglisi, F

Get full text

Strategy of monitoring metastatic breast cancer (M-MBC) in clinical practice: more or less intensive? by Vitale, M G, Bonotto, M, Gerratana, L, Basile, D, Bartoletti, M, Pelizzari, G, Fanotto, V, Lisanti, C, Bozza, C, Cinausero, M, Iacono, D, Poletto, E, Barban, S, Mansutti, I, Minisini, A M, Russo, S, Andreetta, C, Mansutti, M, Fasola, G, Puglisi, F

Get full text

Final results from CAMEO-PRO study: complementary and alternative medicine in oncology. physicians inform oncological patients by Bozza, C., Gerratana, L., Basile, D., De Carlo, E., Cortiula, F., Pella, N., Vitale, M.G., Bartoletti, M., Russo, S., Bonotto, M., Cinausero, M., Fanotto, V., Pelizzari, G., Minisini, A.M., Andreetta, C., Mansutti, M., Iacono, D., Sottile, R., Fasola, G., Puglisi, F.

Get full text

Monitoring metastatic breast cancer (M-MBC) during treatment: a GIM (Gruppo Italiano Mammella) survey by Bonotto, M, Basile, D, Gerratana, L, Pelizzari, G, Bartoletti, M, Vitale, M G, Fanotto, V, Lisanti, C, Bozza, C, Cinausero, M, Andreetta, C, Russo, S, Mansutti, M, Minisini, A M, Merlini, L, De Laurentiis, M, Montemurro, F, Fasola, G, Del Mastro, L, Puglisi, F

Get full text

Neutrophil-to-lymphocyte ratio in metastatic breast cancer patients: relationship with tumor characteristics and survival by Bartoletti, M, Gerratana, L, Zago, S, Basile, D, Fanotto, V, Vitale, M G, Pelizzari, G, Bonotto, M, Bozza, C, Lisanti, C, Cinausero, M, Barban, S, Lera, M, Venuti, I, Mansutti, M, Minisini, A M, Fasola, G, Curcio, F, Puglisi, F

Get full text

Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole by Sini, V, Lunardi, G, Cirillo, M, Turazza, M, Bighin, C, Giraudi, S, Levaggi, A, Piccioli, P, Bisagni, G, Gnoni, R, Stridi, G, Porpiglia, M, Picardo, E, Ponzone, R, Marenco, D, Mansutti, M, Puglisi, F, Del Mastro, L

“…Background: Obesity is an independent adverse prognostic factor in early breast cancer patients, but it is still controversial whether obesity may affect…”
Get full text

Taxane-induced nail changes: incidence, clinical presentation and outcome by Minisini, A. M., Tosti, A., Sobrero, A. F., Mansutti, M., Piraccini, B. M., Sacco, C., Puglisi, F.

“…The clinical characteristics of nail changes in seven patients receiving taxane-containing chemotherapy are described. They include nail pigmentation,…”
Get full text

1864 Chemotherapy versus endocrine therapy as first line treatment in patients with luminal-like metastatic breast cancer. Impact on survival by Bonotto, M, Gerratana, L, Arpino, G, Di Maio, M, De Angelis, C, Iacono, D, Cinausero, M, Milano, M, Gargiulo, P, Fontanella, C, Bozza, C, Moroso, S, Minisini, A.M, Mansutti, M, Fasola, G, De Placido, S, Puglisi, F

Get full text

1890 Look up the meaning of distinct circulating tumor cells in metastatic breast cancer by Gerratana, L, Bulfoni, M, Beltrami, A.P, Di Loreto, C, Bonotto, M, Cinausero, M, Isola, M, Toffoletto, B, Marzinotto, S, Minisini, A.M, Sottile, R, Banzi, M, Peruzzi, E, Mansutti, M, Fasola, G, Puglisi, F, Cesselli, D

Get full text

1227 Risk of unplanned presentations and hospital admission of breast cancer outpatients by Fontanella, C, Fanotto, V, De Carlo, E, Iacono, D, Bozza, C, Bonotto, M, Cinausero, M, Gerratana, L, Guardascione, M, Russo, S, Andreetta, C, Moroso, S, Minisini, A.M, Mansutti, M, Aprile, G, Fasola, G, Puglisi, F

Get full text

1860 Last-line treatment of advanced breast cancer: Which clinical characteristics maypredict the outcome? by Cinausero, M, Gerratana, L, Iacono, D, Bonotto, M, Bozza, C, Bolzonello, S, Fanotto, V, Poletto, E, Fontanella, C, Guardascione, M, Minisini, A.M, Russo, S, Andreetta, C, Moroso, S, Sottile, R, Mansutti, M, Fasola, G, Puglisi, F

Get full text

Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole by Lunardi, G., Piccioli, P., Bruzzi, P., Notaro, R., Lastraioli, S., Serra, M., Marroni, P., Bighin, C., Mansutti, M., Puglisi, F., Porpiglia, M., Ponzone, R., Bisagni, G., Garrone, O., Cavazzini, G., Clavarezza, M., Del Mastro, L.

“…Estrogen synthesis suppression induced by aromatase inhibitors in breast cancer (BC) patients may be affected by single nucleotide polymorphisms (SNPs) of the…”
Get full text

Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer by Puglisi, F., Cardellino, G.G., Crivellari, D., Di Loreto, C., Magri, M.D., Minisini, A.M., Mansutti, M., Andreetta, C., Russo, S., Lombardi, D., Perin, T., Damante, G., Veronesi, A.

“…Preclinical data have indicated a synergistic interaction between docetaxel and capecitabine by means of taxane-induced up-regulation of thymidine…”
Get full text

Neo-adjuvant exemestane in elderly patients with breast cancer: a phase II, multicentre, open-label, Italian study by Mustacchi, G., Mansutti, M., Sacco, C., Barni, S., Farris, A., Cazzaniga, M., Cozzi, M., Dellach, C.

“…Background: The steroidal aromatase inhibitor exemestane has demonstrated efficacy for the treatment of breast cancer in the metastatic and adjuvant settings…”
Get full text

A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer by Venturini, M, Bighin, C, Puglisi, F, Olmeo, N, Aitini, E, Colucci, G, Garrone, O, Paccagnella, A, Marini, G, Crinò, L, Mansutti, M, Baconnet, B, Barbato, A, Del Mastro, L

“…Abstract To evaluate the cardiotoxicity, general toxicity, and activity of non-pegylated liposomal doxorubicin, in combination with docetaxel and trastuzumab,…”
Get full text

A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer by Cresta, S., Grasselli, G., Mansutti, M., Martoni, A., Lelli, G., Capri, G., Buzzi, F., Robustelli Della Cuna, G., Jirillo, A., Terzoli, E., Frevola, L., Tarenzi, E., Sguotti, C., Azli, N., Murawsky, M., Gianni, L.

“…Background: This randomized phase II study was conducted to evaluate the efficacy of doxorubicin and docetaxel (DOC) administered either as a combination, an…”
Get full text